Sign in
CompletedNo phase

Host Dysregulation-Driven Sepsis Prediction Model

Key facts

Who runs it
Second Affiliated Hospital of Wenzhou Medical University
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
1,000 people enrolled
Started
1 Sept 2024
Ended
17 Oct 2024
Type of study
Observational, 2 groups
Treatments tested
  • Tumor Necrosis Factor
  • Interleukin-1β
  • Interleukin-12
  • Interleukin-18
  • Complement C3
  • Complement C5
Record updated
31 October 2024

Who can take part

Age
18 years and older
Sex
Women and men

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Patients with Infection or Suspected Infection

Who cannot take part

  • Patients with Autoimmune Diseases
  • Patients with Advanced-Stage Cancer and Systemic Metastasis
  • Pregnant Women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to identify risk factors associated with sepsis and to construct a predictive model for sepsis. This will provide an objective theoretical and empirical foundation for the diagnosis, assessment, and management of sepsis in our country.The primary questions addressed are:

Read full original descriptionShow less

What are the risk factors for the development of sepsis? How do we improve the prognosis of sepsis?

The 2 groups in the trial

  • Sepsis Group

    Treatment: Tumor Necrosis Factor, Interleukin-1β, Interleukin-12, Interleukin-18, Complement C3, and Complement C5

  • Non-Sepsis Group

    Treatment: Tumor Necrosis Factor, Interleukin-1β, Interleukin-12, Interleukin-18, Complement C3, and Complement C5

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Construction and Validation of a Sepsis Prediction Model Based on Dysregulation of Host Response
Record updated
31 October 2024